The server is under maintenance between 08:00 to 12:00 (GMT+08:00), and please visit later.
We apologize for any inconvenience caused
Login  | Sign Up  |  Oriprobe Inc. Feed
China/Asia On Demand
Journal Articles
Laws/Policies/Regulations
Companies/Products
Bookmark and Share
zhong zu ren xing zhong liu huai si yin zi shou ti kang ti fc rong he dan bai zhi liao you nian te fa xing guan jie yan de lin chuang xiao ying
Author(s): 
Pages: 825-827
Year: Issue:  5
Journal: The Journal of Practical Medicine

Keyword:  关节炎幼年型类风湿生物制剂;
Abstract: 目的:研究重组人Ⅱ型肿瘤坏死因子受体-抗体Fc融合蛋白(商品名益赛普)治疗非全身型幼年特发性关节炎(JIA)的临床疗效。方法:70例非全身型JIA患儿分为试验组和对照组。试验组皮下注射益赛普,对照组口服甲氨蝶呤。治疗后进行疗效及放射学改变评估。结果:(1)试验组中多关节型及ERA型治疗后1、3、6个月ACR Pedi 30、50、70达标率均显著高于对照组(P <0.05),CRP、ESR显著低于对照组(P <0.05);少关节型除治疗后1个月CRP、6个月ESR较对照组降低外(P <0.05),其余指标与对照组比较差异无统计学意义(P >0.05)。(2)试验组中除少关节型治疗后3个月ESR与治疗前比较差异无统计学意义外,其余指标各时间点均较治疗前明显降低(P <0.05)。(3)试验组放射学改变较对照组及治疗前均明显改善(P <0.05)。结论:益赛普联合传统药物治疗非全身型JIA具有良好的安全性和有效性,临床疗效优于单纯传统治疗,能更快、更有效地降低炎性指标,并能减轻放射学改变,尤其对多关节型及ERA型患儿具有更优的效益/价值比。
Related Articles
No related articles found